Upstream Bio, Inc. (UPB)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Developing Treatments for Inflammatory Diseases	2.37M	2.38M	1.21M
Developing Treatments for Inflammatory Diseases Growth	-0.42%	96.37%	-
Total	2.37M	2.38M	1.21M
Total Growth	-0.42%	96.37%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
United States	2.37M	2.38M	1.21M
United States Growth	-0.42%	96.37%	-
Total	2.37M	2.38M	1.21M
Total Growth	-0.42%	96.37%	-

Source: S&P Global Market Intelligence.